Who You Gonna Call For US Oral Contraceptive Switch? Former FDA Official Heads Perrigo Americas
Jim Dillard, chief scientific officer for Perrigo since 2019, moves to head the North American business with research and development experience as well as a regulatory background from his work at the FDA.
You may also be interested in...
July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.
HRA’s approval for pharmacy sales of a daily oral contraceptive the UK and its ongoing work on an NDA to propose making another progestin-only contraceptive ingredient available OTC in the US stand out as additions to Perrigo’s business with the most substantial revenue impacts.
Ireland’s Office of Revenue concluded it “would not object if the Tax Appeals Commission adjusted the amount of the assessment to less than €1 billion,” says Perrigo CEO Murray Kessler.